Shownotes
This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myeloproliferative neoplasms (MPNs). Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses mechanisms of disease progression, the DUSP6-RSK1 signaling pathway as a therapeutic target, and the ongoing debate around early versus late intervention in MPNs. Hélène Gleitz, PhD, Erasmus MC, Rotterdam, Netherlands, shares insights into the role of the bone marrow microenvironment and fibrotic niches in disease…
Website: vjhemonc.podbean.com

